Mortality in intracoronary versus intravenous abciximab - Authors' reply

Holger Thiele; Ingo Eitel; Oana Brosteanu; Steff En Desch; Gerhard Schuler

doi:10.1016/S0140-6736(12)61121-0

Mortality in intracoronary versus intravenous abciximab - Authors' reply

Holger Thiele^*, Ingo Eitel, Oana Brosteanu, Steff En Desch, Gerhard Schuler

^*Corresponding author for this work

Department of Internal Medicine II

University of Leipzig

Original language	English
Journal	The Lancet
Volume	380
Issue number	9836
Pages (from-to)	26
Number of pages	1
ISSN	0140-6736
DOIs	https://doi.org/10.1016/S0140-6736(12)61121-0
Publication status	Published - 07.2012

Funding

HT has received an unrestricted grant from Lilly, and speaker's fees from Lilly, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, and the Medicines Company. All other authors declare that they have no conflicts of interest.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Centers: Cardiological Center Luebeck (UHZL)

DFG Research Classification Scheme

2.22-12 Cardiology, Angiology

Access to Document

10.1016/S0140-6736(12)61121-0

Cite this

@article{bbf049dc01ca4f1d86d24d1db887880c,

title = "Mortality in intracoronary versus intravenous abciximab - Authors' reply",

author = "Holger Thiele and Ingo Eitel and Oana Brosteanu and \{En Desch\}, Steff and Gerhard Schuler",

note = "Funding Information: HT has received an unrestricted grant from Lilly, and speaker's fees from Lilly, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, and the Medicines Company. All other authors declare that they have no conflicts of interest.",

year = "2012",

month = jul,

doi = "10.1016/S0140-6736(12)61121-0",

language = "English",

volume = "380",

pages = "26",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "9836",

}

TY - JOUR

T1 - Mortality in intracoronary versus intravenous abciximab - Authors' reply

AU - Thiele, Holger

AU - Eitel, Ingo

AU - Brosteanu, Oana

AU - En Desch, Steff

AU - Schuler, Gerhard

N1 - Funding Information: HT has received an unrestricted grant from Lilly, and speaker's fees from Lilly, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, and the Medicines Company. All other authors declare that they have no conflicts of interest.

PY - 2012/7

Y1 - 2012/7

UR - https://www.scopus.com/pages/publications/84863431198

U2 - 10.1016/S0140-6736(12)61121-0

DO - 10.1016/S0140-6736(12)61121-0

M3 - Letters

AN - SCOPUS:84863431198

SN - 0140-6736

VL - 380

SP - 26

JO - The Lancet

JF - The Lancet

IS - 9836

ER -

Mortality in intracoronary versus intravenous abciximab - Authors' reply

Funding

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Access to Document

Other files and links

Cite this